Summary
There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases, targeting approximately 5% of the celiac disease patient population and there are no preventative medications.
The anticipated launch of Alba/Teva’s larazotide acetate in 2018 in the US and 2019 in 5EU, followed by the launch of Alvine/AbbVie’s latiglutenase in 2019 and 2020 in the US and 5EU respectively are set to change the management of the disease and drive growth in the celiac disease market. Both drugs are expected to target patients who undergo gluten exposure while on a GFD equating to approximately 95% of the celiac disease patient population.
Read Complete Report with TOC: http://www.radiantinsights.com/research/opportunityanalyzer-celiac-disease-opportunity-analysis-and-forecast-to-2023
GlobalData estimates that the uptake of both drugs will be equally high, but latiglutenase will rapidly gain market value and emerge the commercially stronger drug with the backing of Immune-Gastro veteran AbbVie.
Highlights
Key Questions Answered
- (Q.) How will the celiac disease market landscape change within the 2013-2018 and the 2013-2023 forecast periods in the 6MM?
- (Q.) What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the celiac disease market?
- (Q.) How do the clinical and commercial attributes of late-stage pipeline drugs compare to one another and against existing treatment options?
- (Q.) What are the significant unmet needs in the celiac disease market?
- (Q.) What are the remaining opportunities in the celiac disease market?
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases, targeting approximately 5% of the celiac disease patient population and there are no preventative medications.
The anticipated launch of Alba/Teva’s larazotide acetate in 2018 in the US and 2019 in 5EU, followed by the launch of Alvine/AbbVie’s latiglutenase in 2019 and 2020 in the US and 5EU respectively are set to change the management of the disease and drive growth in the celiac disease market. Both drugs are expected to target patients who undergo gluten exposure while on a GFD equating to approximately 95% of the celiac disease patient population.
Read Complete Report with TOC: http://www.radiantinsights.com/research/opportunityanalyzer-celiac-disease-opportunity-analysis-and-forecast-to-2023
GlobalData estimates that the uptake of both drugs will be equally high, but latiglutenase will rapidly gain market value and emerge the commercially stronger drug with the backing of Immune-Gastro veteran AbbVie.
Highlights
Key Questions Answered
- (Q.) How will the celiac disease market landscape change within the 2013-2018 and the 2013-2023 forecast periods in the 6MM?
- (Q.) What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the celiac disease market?
- (Q.) How do the clinical and commercial attributes of late-stage pipeline drugs compare to one another and against existing treatment options?
- (Q.) What are the significant unmet needs in the celiac disease market?
- (Q.) What are the remaining opportunities in the celiac disease market?
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment